367 related articles for article (PubMed ID: 17233740)
1. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
Dupont PJ; Warrens AN
Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
[TBL] [Abstract][Full Text] [Related]
2. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
3. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
4. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
[TBL] [Abstract][Full Text] [Related]
5. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells.
Oyaizu N; Kayagaki N; Yagita H; Pahwa S; Ikawa Y
Biochem Biophys Res Commun; 1997 Sep; 238(2):670-5. PubMed ID: 9299572
[TBL] [Abstract][Full Text] [Related]
6. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
O'Connell J
Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
[TBL] [Abstract][Full Text] [Related]
7. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.
Ottonello L; Tortolina G; Amelotti M; Dallegri F
J Immunol; 1999 Mar; 162(6):3601-6. PubMed ID: 10092820
[TBL] [Abstract][Full Text] [Related]
8. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells.
Fujino M; Li XK; Suda T; Hashimoto M; Okabe K; Yaginuma H; Mikoshiba K; Guo L; Okuyama T; Enosawa S; Amemiya H; Amano T; Suzuki S
Xenotransplantation; 2001 May; 8(2):115-24. PubMed ID: 11328582
[TBL] [Abstract][Full Text] [Related]
9. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
Matter-Reissmann UB; Sonntag KC; Gilli UO; Leguern C; Schneider MK; Seebach JD
Xenotransplantation; 2004 Jan; 11(1):43-52. PubMed ID: 14962292
[TBL] [Abstract][Full Text] [Related]
10. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas ligand blocks destructive corneal inflammation in mouse models of corneal epithelial debridement and LPS induced keratitis.
Gregory-Ksander M; Perez VL; Marshak-Rothstein A; Ksander BR
Exp Eye Res; 2019 Feb; 179():47-54. PubMed ID: 30365944
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
14. Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling.
Bremer E; Abdulahad WH; de Bruyn M; Samplonius DF; Kallenberg CG; Armbrust W; Brouwers E; Wajant H; Helfrich W
Immunol Lett; 2011 Aug; 138(2):161-8. PubMed ID: 21514322
[TBL] [Abstract][Full Text] [Related]
15. Chemotactic activity of soluble Fas ligand against phagocytes.
Seino K; Iwabuchi K; Kayagaki N; Miyata R; Nagaoka I; Matsuzawa A; Fukao K; Yagita H; Okumura K
J Immunol; 1998 Nov; 161(9):4484-8. PubMed ID: 9794371
[TBL] [Abstract][Full Text] [Related]
16. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
17. Involvement of IL-17 in Fas ligand-induced inflammation.
Umemura M; Kawabe T; Shudo K; Kidoya H; Fukui M; Asano M; Iwakura Y; Matsuzaki G; Imamura R; Suda T
Int Immunol; 2004 Aug; 16(8):1099-108. PubMed ID: 15237105
[TBL] [Abstract][Full Text] [Related]
18. Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death.
Nakano K; Saito K; Mine S; Matsushita S; Tanaka Y
Apoptosis; 2007 Jan; 12(1):45-54. PubMed ID: 17136494
[TBL] [Abstract][Full Text] [Related]
19. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
20. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
